The Veterinary Medicines Directorate (VMD) has updated the Summary of Product Characteristics (SPCs) for Librela 5mg, 10mg, 15mg, 20mg, and 30mg Solutions for Injection for Dogs. Section 4.6 now includes rare reports of paresis, paralysis, and immune-mediated polyarthritis. A new precaution in Section 4.5 advises caution when treating dogs with pre-existing immune-mediated haemolytic anaemia, immune-mediated polyarthritis, or immune-mediated thrombocytopenia. These updates, effective from 3 February 2026, are available in the VMD Connect medicine updates section. The SPCs provide information on known adverse events under sections 3.6 and 4.6.
© Crown copyright, 2024, GOV.UK.
Summary adapted from content licensed under the Open Government Licence v3.0.
For details, see https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/.
Original source: https://www.gov.uk/
https://www.gov.uk/government/news/librela-solution-for-injection-for-dogs-spc-update
Made by AI. If you spot anything of concern write us at contact@cybach.com. We’ll promptly correct irregularities.